COMPANY

Regenerative Medical Solutions Inc

Keywords: cell therapy metabolic diabetes mellitus

Location: Madison, WI · source · Oct 12, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $872K (SBIR Phase II 5R44DK133008-03, continuation, notice Aug 6, 2026). NIH RePORTER 5R44DK133008-03 (Aug 6, 2026)
Evidence (1 event)
- Aug 6, 2026 · NIH RePORTER 5R44DK133008-03
  Organization: REGENERATIVE MEDICAL SOLUTIONS, INC.; City/State: CHICAGO, IL; Project number: 5R44DK133008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 872115; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 6, 2026 Grant Government grant — SBIR: $872,115 (annual award, as published), announced Aug 6, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 10, 2025 Grant Government grant — SBIR: $915,136 (annual award, as published), announced Sep 10, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Last 2 years.

Aug 6, 2026 Government grant — SBIR: $872,115 (annual award, as published), announced Aug 6, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 10, 2025 Government grant — SBIR: $915,136 (annual award, as published), announced Sep 10, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗